Legacy Advisors’s Biogen BIIB Stock Holding History

Legacy Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24	Closed	-$8K	–	145
2018 Q3	$8K	Buy	+24	New	+$8.26K	﹤0.01%	368
2017 Q4	–	Sell	-42	Closed	-$13K	–	354
2017 Q3	$13K	Buy	+42	New	+$12.4K	0.01%	194

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Legacy Advisors's BIIB Position: Q4 2018 in Review

Legacy Advisors sold out of Biogen (BIIB) in Q4 2018, closing a stake of 24 shares — an estimated $8K sold.

Legacy Advisors first reported a position in BIIB in Q3 2017 and held it in 2 quarters. The position peaked at $13K in Q3 2017. 1,141 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

Legacy Advisors reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
Legacy Advisors sold 24 Biogen shares in Q4 2018, an estimated $8K.
Legacy Advisors first reported a position in Biogen in Q3 2017 and held it in 2 quarters.
Legacy Advisors's Biogen position peaked at $13K in Q3 2017.
1,141 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Legacy Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.